New technologies are often fascinating not in what new capabilities they bring to the table, but rather how they can be utilized to provide new solutions to existing industries. SANUWAVE Health, Inc. ($SNWV), a developer of high-energy, focused, shock wave technology designed for medical purposes, originally engineered their technology to be used within the medical sector for the repair and regeneration of tissue, musculoskeletal, and vascular structures. However, the company has announced a recent development that could revolutionize the livestock industry and expand the potential uses of their shock wave technology into yet another new territory.
The Georgia-based company announced that their “Methods for Cleaning and Tenderizing Animal Meat with Shock Waves” has received the U.S. Patent Number 9,095,632 from the U.S. Patent and Trademark Office. The patent, which has a life that extends through 2030, includes twenty cases for the use of shock waves to both decontaminate and tenderize animal meat.
The company’s newly awarded patent demonstrates that animal meat, sealed in vacuum bags, can be cleaned and tenderized with manual or computer controlled application of shockwaves. Typically, cleaning and tenderizing involves a long refrigeration process that could take days, or even weeks, to complete. Sanuwave’s shock wave technology dramatically reduces that timeframe, saving on energy costs.
"This new patent continues to extend the reach of our technology beyond regenerative medicine into food processing field and fits with our long term strategy to maximize the value of our shock wave technology in non-medical fields,” said Kevin A. Richardson II, Chairman of the board of directors of SANUWAVE. “The shock wave methods described in this patent save energy and also allow farmers to raise more grass-fed livestock that yield leaner, tougher meat, which can dramatically reduce the demand for energy-intensive feed corn, to mention only few advantages.”
This announcement follows a number of positive updates from the company. SANUWAVE’s proprietary technology, Pulsed Acoustic Cellular Expression (PACE), is used for both medical and non-medical applications. This past July, Sanuwave presented positive results during the 2015 Biofilm Science and Technology Meeting on the effectiveness of their Shock Wave Technology for Biofilm Removal. Also, in June, the company received positive feedback from the U.S. Food and Drug Administration (FDA) regarding the supplemental clinical trial of their wound care technology, dermaPACE, to treat diabetic foot ulcers.
With Sanuwave adding their 45th patent, the livestock industry will have access to a technology that allows for the production of a superior product at a lower cost. Sanuwave Health continues their winning streak by being an innovator in two vital industries.
To learn more about Sanuwave, visit www.sanuwave.com.
Disclosure: In the purview of Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention the fact that Equities.com, Inc. may be compensated by the companies profiled in the Spotlight Companies section. The purpose of these profiles is to provide awareness of these companies to investors in the micro, small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. Equities.com is not a registered broker, broker dealer, investment advisor, analyst, investment banker or underwriter. All profiles are based on information that is available to the public. The information contained herein should not be considered to be all-inclusive and is not guaranteed by Equities.com to be free from misstatement or errors. Readers are reminded to do their own due diligence when researching any companies mentioned on this website.
DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer